Jiayuh Lin, Ph.D.

View CV »

Gender:

• Male

Languages Spoken:

• English

Research Center:

• Center for Childhood Cancer

Areas of Interest:

• My laboratory studies the cancer biology of Signal Transducer and Activator of Transcription 3 (STAT3) oncogenic pathway and STAT1 tumor suppressor in human cancers. Constitutive activation of STAT3 is frequently detected in most types of human cancers. We are studying the activation of STAT3 by upstream tyrosine kinases, HGF and SDF-1 and how they may function in STAT3-mediated cell survival, proliferation, tumor angiogenesis, and tumor cells/stroma fibroblasts interaction in cancer cells. The laboratory is also developing novel structure-based design of small molecule compounds that selectively target STAT3 oncogenic pathway in cancer cells as a new cancer therapeutic approach. Further, we are examining the interaction between STAT1 and p53 tumor suppressor and how they cooperate to mediate tumor suppression in cancer cells.

Post Doctoral

• University of Delaware, Department of Biological Sciences
  Date Completed: 06/30/1991

Post Doctoral

• Princeton University, Department of Molecular Biology
  Date Completed: 06/30/1996

2005–present

• Associate Professor with Tenure, Department of Pediatrics, College of Medicine and Public Health, Ohio State University.

2005–present

• Investigator, Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital.

2005–present

• Graduate Faculty, Integrated Biomedical Science, Molecular, Cellular & Developmental Biology, and Ohio State Biochemistry Graduate Programs, Ohio State University.

2001–2004

• Graduate Faculty in Cellular and Molecular Biology Graduate Program and Cancer Biology Training Program at the University of Michigan Health System.

1998–2004

• Assistant Professor (Tenure Track) at the Division of Gynecologic Oncology, University of Michigan Comprehensive Cancer Center.

1997–1998

• Research Investigator/Instructor, Department of Dermatology, University of Michigan Medical Center.

• Li, J, Liu, A, Xu, Y, Lin, J, Jou, D, Li, C. 2011. Fragment-based drug design and drug respositioning using multiple ligand simultaneous docking (MLSD): Identifying celecoxib and template compounds as novel inhibitors of STAT3.  J Medicinal Chemistry. Vol. 54. : 5592-5596.
• Abuzeid WM, Davis S., Tang A., Saunders L., Brenner JC., Lin J., Fuchs J.R., Light E., Bradford CR., Prince M., Carey TE. 2011. Sensitization of head and neck cancer to cisplatin through the inhibition of STAT3.  Archives of Otolaryngology-Head & Neck Surgery. Vol. 5, no. 137. : 499-507.
• Reed S., Li H., Li C., and Lin J. 2011. Celecoxib Inhibitis STAT3 Phosphorylation and Suppresses Cell Migration and Colony Forming Ability in Rhabdomyosarcoma Cells.  Biochemical Biophysics Research Communications. Vol. 3, no. 407. : 450-455.
• Onimoe GI., Liu A., Lin L., Wei CC., Schwartz EB., Bhasin D., Li C., Fuchs JR., Li P-K, Houghton P., Termuhlen A., Gross T., and Lin J.,. 2011. Small molecules, LLL12 and FLLL32 inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.  Investigational New Drugs.
• Lin, L., Benson, D.M., Jr., DeAngelis, S., Bakan, C.E., Li, P-K., Li, C., and Lin J. 2011. A small moleule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.  International Journal of Cancer.
• Liu Y., Liu A., Li H., Li C. and Lin J. 2011. Celecoxib Inhibits Constitutive and Interleukin 6-Induced STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cell.  Cancer Prevention Research. Vol. 4. : 1296-1305.
• Liu Y., Lin J.,. 2011. Blocking the IL-6-STT3 signaling pathway: potential liver cancer therapy.  Future Oncology. Vol. 7. : 161-164.
• Liu Y., Liu A., Xu Z., Yu W., Wang H., Li C., and Lin J. 2011. XZH-5 Inhibits STAT3 Phosphorylation and Causes Apoptosis in Human Hepatocellular Carcinoma Cells.  Apoptosis. Vol. 16. : 502.
• Wei C., Ball S., Lin L., Liu A., Fuchs JR., Li PK., Li C., Lin J.,. 2011. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.  International Journal of Oncology. Vol. 38. : 279-285.
• Lin, L, Liu, Y, Li, P-K, Fuchs, J, Shibata, H, Iwabuhi, Y, Lin, J. 2011. Targeting colon cancer stem-like cells using a new curcumin analog, GO-Y030.  British Journal of Cancer. Vol. 2, no. 105. : 212-220.
• Lin, L., Fuchs, J., Li, C., Olson, V., Bekaii-Saab, T., Lin, J. 2011. STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells.  Biochem and Biophysical Res Comm. (Formally Accepted)
• Fossey S., Bear M., Lin J., Li C., Schwartz E., Li P-K, Fuchs J., Fenger J., Kulp S., Kisseberth WC., and London C. 2011. The Novel Curcumin Analog FLLL32 has Biologic Activity Against Osteosarcoma.  BMC Cancer. Vol. 1, no. 11. : 112.
• Ball S., Li C., and Lin J.,. 2011. The small molecule inhibitor, LLL12 inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.  PLoS One. Vol. 4, no. 6. : e18820.
• Lin, L, Liu, A, Peng, Z, Lin, H, Li, C, Li, P-K, Lin, J. 2011. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells.  Cancer Research.
• Liu A., Liu Y., Xu Z., Wenying Yu W., Wang H., Li C., and Lin J. 2011. A Novel Small Molecule, XZH-5 Inhibits Constitutive and Interleukin-6-Induced STAT3 Phosphorylation in Human Rhabdomyosarcoma Cells.  Cancer Science.
• Liu, A, Liu, Y, Li, P-K, Li, C, Hu, Q, Lin, J. 2011. LLL12 inhibits interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells.  Anticancer Research. Vol. 6, no. 31. : 2029-2035.
• Liu Y., Li P-K., Li C., and Lin J. 2010. Inhibition of IL-6/STAT3 Signaling in Human Liver Cancer Cells Blocks the Anti-Apoptotic Activity of IL-6.  J. Biol. Chem.. (June 18)
• Lin L., Hutzen B, Ball S., Zuo M., Deangelis S., Foust E., Pandit B, Ihnat MA, Shenoy S., Kulp S., Li P-K., Li C., Fuchs J., and Lin J. 2010. Novel STAT3 phosphorylation inhibitors exhibit potent growth suppressive activity in breast and pancreatic cancer cells.  Cancer Research. Vol. 70. (March): 2445-2454. (IF: 7.514)
• Lin L., Hutzen B, Ball S., Sobo M., Foust E., Deangelis S., Friedman L., Cen L., Fuchs J., Li P-K., Li C., and Lin J. 2010. A novel small molecule, LLL12 inhibits STAT3 activities and induces apoptosis in human breast and pancreatic cancer cells.  Neoplasia. Vol. 12: 39-50. (IF: 5,9)
• Liu, Y, Li, P-K, Li, C, Lin, J. 2010. IL-6 is a risk factor in Human Liver Cancer Cells.  Cell Cycle. Vol. 9. : 3423-3427.
• Lin, L, Hutzen, B, Ball S, DeAngelis, S, Foust, E, Li, P-K, Li, C, Hoyt, D, Lesinski, G, Fushcs, J, Lin, J. 2010. FLLL32 inhibits STAT3 phosphorylation and activity and exhibits potent growth suppressive activity in human cancer cells.  Molecular Cancer. Vol. 9. : 217.
• Liu, Y, Li, C, Lin, J. 2010. STAT3 as a therapeutic target for glioblastoma.  Anticancer Agents Med Chem. Vol. 10. : 512-519.
• Bill, MA, Fuchs, JR, Li, C., Bakan, C., Brown, Jr, DM, Schwartz, EB, Lin, J, Hoyt, DG, Fossey, SL, Young, GS, Carson III, WE, Li-P-K, Lesinski, GB. 2010. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.  Molecular Cancer. Vol. 9: 165.
• Fuh B., Sobo M., Cen L, Sobo M., Josiah D., Hutzen B., Cisek K., Bhasin D., Regan N., Chan C, Caldas H., Li C., Li P., and Lin J. 2009. LLL-3 inhibits STAT3 activity, suppresses glioblastoma multiforme cell growth and prolongs survival in a mouse glioblastoma multiforme model.  British Journal of Cancer. Vol. 100. (January 13): 106-112. (IF: 4.846)
• Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, Li C, Chan KK. 2009. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett., no. Epub 2008 Dec 14. (IF: 2.604)
• Fuchs J., Pandit B., Bhasin D., Etter J., Regan N., Abdelhamid D., Li C., Lin J., P Li. 2009. Structure-activity relationship studies of curcumin analogues.  Bioorganic & Medicinal Chemistry Letters. Vol. 19: 2065-2069. (IF: 2.604)
• Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li P-K, Kisseberth WC, and London CA. 2009. Characterization of STAT3 activation and expression in canine and human osteosarcoma.  BMC Cancer. Vol. 9: 81. (IF: 3.08)
• Hutzen, B, Williams, B, Jones, S, Cen, L, Deangelis, S, Fuh B, Lin, J. 2009. Dietary agent, benzyl isothiocyanate inhibits STAT3 phosphorylation and collaborates with sulforaphane in the growth suppression of PANC-1 human pancreatic cancer cells.  Cancer Cell International. Vol. 24, no. 9.
• Liu Z., Xie Z., Jones W., Pavlovicz RE., Liu S., Yu J., Li P-K., Lin J., Fuchs JR., Marcucci G., Li C., Chan KK. 2009. Curcumin is a potent DNA hypomethylation agent.  Bioorganic & Medicinal Chemistry Letters. Vol. 19. : 706-709. (IF: 2.604)
• Hutzen B., Friedman L., Cen L., Sobo M., Deangelis S., Lin L., Shibata H., Iwabuchi Y., and Lin J. 2009. A new curcumin analogue, GO-Y030 exhibits potent growth suppressive activity and inhibits STAT3 phosphorylation in breast and pancreatic carcinoma cells.  International J. Oncology. Vol. 35: 867-872. (IF: 2.295)
• Lin L., Hutzen B, Ball S., Foust E., Sobo M., Deangelis S., Pandit B., Friedman L., Li C., Li P-K., Fuchs J., and Lin J. 2009. Curcumin analogues exhibit enhanced growth suppressive activity and inhibit AKT and STAT3 phosphorylation in breast and prostate cancer cells.  Cancer Science. Vol. 100: 1719-1727. (IF: 3.829)
• Canner J., Sobo M, Ball S, Hutzen B, Willis W., Studebaker, Wang S., Yang D., and Lin J. 2009. Inhibition of MDM2 oncoprotein by a novel small molecule inhibitor, MI-63 in rhabdomyosarcoma cells.  British Journal of Cancer. Vol. 101: 774-781. (IF: 4.846)
• Friedman L., Lin L., Ball S., Bekaii-Saab T., Fuchs J., Li P., Li C., and Lin J. 2009. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells.  Anti-Cancer Drugs.. Vol. 20: 444-449. (IF: 2.358)
• Cen L., Hutzen B., Ball S., DeAngelis S., Chen C., Fuchs JR, Li C., Li P., and Lin J. 2009. New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells.  BMC Cancer. Vol. 9: 99. (IF: 3.08)
• Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, Loy A, Huang V, Cheng G, Lin J. 2008. . Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. Vol. 7. (October): 78. (IF: 3.693)
• Lieblein JC, Ball S, Hutzen B, Sasser AK, Lin HJ, Huang TH, Hall BM, Lin J. 2008. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer. Vol. 8. (October): 302. (IF: 2.709)
• Chan C, Lin HJ, Lin J. 2008. Stress-associated hormone, norepinephrine, increases proliferation and IL-6 levels of human pancreatic duct epithelial cells and can be inhibited by the dietary agent, sulforaphane. Int J Oncol.. Vol. 33, no. 2. (August): 415-419. (IF: 2.295)
• Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, Lin J, Li PK. 2008. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett.. Vol. 18, no. 1. (January): 391-395. (IF: 2.604)
• Chen, CL, Cen, L, Kohout, J, Hutzen, B, Chan, C, Hsieh, FC, Loy, A, Huang, V, Cheng, G, Lin, J. 2008. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival.  Mol Cancer. Vol. 78, no. 7.
• Cen L, Lin H, Chen C, Qualman SJ, and Lin J. 2007. Inhibition of PDK-1/AKT pathway by a PDK-1 small molecular inhibitor in rhabdomyosarcomas cells. British Journal of Cancer. Vol. 97: 785-791.
• Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, Lin J, Li PK. 2007. Design, synthesis, and studies of small molecule STAT3 inhibitors.  Bioorganic & Medinical Chemistry Letters.
• Cen L, Arnoczky KJ, Hsieh FC, Lin HJ, Qualman SJ, Yu S, Xiang H, Lin J. 2007. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Modern Pathology. Vol. 20, no. 9: 936-946.
• Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, Lin J. 2007. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer.
• Chen C, Hsieh F, Lieblein JC, Brown J, Chan C, Wallace J, Cheng G, Hall B, and Lin J. 2007. Stat3 activation in human endometrial and cervical cancers. British Journal of Cancer. Vol. 96: 591-599.
• Cen L, Arnoczky K, Hsieh F, Lin H, Qualman S, Yu S, Xiang H, Lin J. 2007. Phosphorylation Profiles of Protein Kinases in Rhabdomyosarcoma. Modern Pathology. Vol. 20, no. 9: 936-946.
• Tang, H, Jin, X, Wang, S, Yang, D, Cao, Y, Chen, J, Gossett, D, Lin, J. 2006. Inhibition of AKT pathway in ovarian cancer cells by a small molecular compound.  Gynecologic Oncology. Vol. 100. : 308-317.
• Chen, C, Hsieh, F, Lin, J. 2006. Systemic evaluation of total Stat3 and Stat3 tyrosine phosphorylation in normal human tissues.  Exp Mol Pathology. Vol. 80. : 295-305.
• Lin, H, Hsieh, F, Song, H, Lin, J. 2005. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer.  British Journal of Cancer. Vol. 93. : 1372-1381.
• Gossett, D, Bradly, M, Jin, X, Lin, J. 2005. 17-Allyamino-17-Demethoxygeldanamycin and 17-NN-Dimethyl Ethylene Diamine-Geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.  Gynecolgic Oncology. Vol. 96. : 381-388.
• Hsieh, F, Cheng, G, Lin, J. 2005. Evaluation of potential Stat-3 regulated genes in human breast cancer.  Biochemical Biophysics Research Communications. Vol. 335. : 292-299.
• Raja, S, Kohout, J, Beer, D, Lin, J, Watkins, SC, Robbins, PD, Billiar, TR, Hughes, SJ. 2005. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma.  Journal of Surgery Research. Vol. 123. : 302-311.
• Song, H, Wang, R, Wang, S, Lin, J. 2005. A small molecule inhibitor discovered through virtual database screening inhibits Stat3 oncogenic function in breast cancer cells.  Proc Natl Acad Sci USA. Vol. 102. : 4700-4705.
• Tang, H, Sondak, V, Lin, J. 2004. A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin.  British Journal of Cancer. Vol. 90. : 1285-1292.
• Jin, X, Gossett, D, Wang, S, Yang, D, Reynolds, RK, Lin, J. 2004. Inhibition of AKT pathway in endometrial cancer cells harboring PTEN mutation by an AKT small molecular inhibitor.  British Journal of Cancer. Vol. 91. : 1808-1812.
• Song, H, Jin, X, Lin, J. 2004. Stat3 up-regulates MEK5 expression in human breast cancer cells.  Oncogene. Vol. 23. : 8301-8309.
• Reid, T, Jin, X, Song, H, Tang, H, Reynolds, RK, Lin, J. 2004. Modulation of JAK2 pathway by p53.  Biochemical Biophysics Research Communications. Vol. 321. : 441-447.
• Song, H, Ethier, SP, Dziubinsky, M, Lin, J. 2004. Stat3 modulates heat shock 27kD protein expression in breast epithelial cells.  Biochemical Biophysics Research Communications. Vol. 314. : 143-150.
• Song, H, Sondak, V, Barber, D, Lin, J. 2004. Inhibition of JAK2 pathway by cisplatin.  International J Oncology. Vol. 24. : 1017-1026.
• Lin J, Jin X, Gossett D, Wang S. 2003. Inhibition of AKT oncogenic pathway in endometrial cancer cells. In Cell and Molecular Biology of Endometrial Carcinoma. Tokyo, Japan: Springer-Verlag Tokyo. 139-149.
• Lin, J, Tang, T, Jin, X, Hsieh, J. 2002. P53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.  Oncogene. Vol. 21. : 3082-3088.
• Lin, J, Jin, X, Rothman, K, Lin, H, Burke, WM. 2002. Inhibition of Stat3 by p53 tumor suppressor in breast cancer cells.  Cancer Research. Vol. 62. : 376-380.
• Jin, X, Rothman, K, Burke, WM, Lin, J. 2002. Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53.  Anticancer Research. Vol. 22. : 659-664.
• Lu, W, Lin, J, Chen, J. 2002. Expression of p14ARF overcomes tumor resistance to p53.  Cancer Research. Vol. 62. : 1305-1310.
• Lilja, JF, Wu, D, Reynolds, RK, Lin, J. 2001. Growth suppression activity of the PTEN tumor suppressor gene in human endometrial cancer cells.  Anticancer Research. Vol. 21. : 1969-1974.
• Lo, P, Chen, J, Tang, P, Lin, J, Lin, C, Su, L, Wu, C, Chen, T, Yang, Y, Wang, F. 2001. Identification of a mouse thiamine transporter gene as a direct transcriptional target for p52.  J Biol Chem. Vol. 276. : 37186-37193.
• Lin, J, Page, C, Jin, X, Sethi, A, Patel, R, Nunez, G. 2001. The apoptotic activity of pro-apoptotic genes in cancer cells.  Anticancer research. Vol. 21. : 831-840.
• Burke, MW, Jin, X, Lin, H, Huang, M, Liu, R, Reynolds, RK, Lin, J. 2001. Inhibition of constitutively active Stat3 in ovarian and breast cancer cells.  Oncogene. Vol. 20. : 7925-7934.
• Lin, J, Jin, X, Page, C, Sondak, V, Jiang, G, Reynolds, K. 2000. A modified p53 overcomes mdm2-mediated oncogenic transformation.  Cancer Research. Vol. 60. : 5895-5901.
• Pochampally, R, Chen, L, Luftig, R, Lin, J, Chen, J. 2000. Temperature-sensitive mutants of p53 homologs.  Biochemical Biophysics Research Communications. Vol. 279. : 1001-1010.
• Page, C, Lin, H, Jin, Y, Castle, V, Nunez, G, Huang, M, Lin, J. 2000. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.  Anticancer Research. Vol. 20. : 407-416.
• Huang, M, Page, C, Reynolds, KR, Lin, J. 2000. Constitutive activation Stat3 oncogene product in ovarian carcinoma cells.  Gynecologic Oncology. Vol. 79. : 67-73.
• Page, C, Huang, M, Jin, X, Lilja, J, Reynolds, K, Lin, J. 2000. Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells.  International J Oncology. Vol. 17. : 23-28.
• Chung, JH, Kang, S, Varani, J, Lin, J, Fisher, GJ, Voorhees, JJ. 2000. Decreased ERK and increased stress-activated MAP kinase activities in aged human skin in vivo.  J Invest Dermatol. Vol. 115. : 177-182.
• Fisher, GJ, Talwar, H, Lin, J, Voorhees, JJ. 1999. Molecular mehcanisms of photoaging in human skin in vivo and their prevention by all-trans retinoic acid.  Photochemistry and Photobiology. Vol. 69. : 154-157.
• Fisher, GJ, Talwar, H, Lin, J, Voorhees, JJ, et al. 1998. Retinoic acid inhibits of c-Jun protein ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin invivo.  J of Clinical Investigation. Vol. 101. : 1432-1440.
• Lin, J, Reichner, C, Wu, X, Levine, AJ. 1996. Analysis of wild-type and mutant p21WAF1 gene activities.  Mol Cell Biol. Vol. 16. : 1786-1793.
• Chen, J, Wu, X, Lin, J, Levine, AJ. 1996. Mdm2 inhibits the G1 growth arrest and apoptosis functions of the p53 tumor suppressor protein.  Mol Cell Biol. Vol. 16. : 2445-2452.
• Chen, J, Lin, J, Levine, AJ. 1995. The ability of mdm2 to complex with p53 is required for the inhibition of transcription activation and suppression activities of p53.  Molecular Medicine. Vol. 1. : 142-152.
• Lin, J, Teresky, A, Levine, AJ. 1995. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.  Oncogene. Vol. 10. : 2387.
• Sabbatini, P, Lin, J, Levine, AJ, White, E. 1995. Essential role for p53-mediated transcription in E1A-induced apoptosis.  Genes & Development. Vol. 9. : 2184-2192.
• Levin, AJ, Wu, MC, Chang, A, Silver, A, Attiyeh, EF, Lin, J, Epstein, CB. 1995. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype.  Ann NY Acad Sci. Vol. 768. : 111-128.
• Lin, J, Wu, X, Chen, J, Chang, A, Levine, AJ. 1994. The functions of the p53 protein in growth regulation and tumor suppression.  Cold Spring Harbor Symp Quan Biol. Vol. 59. : 215-223.
• Lin, J, Chen, J, Elenbass, B, Levin, AJ. 1994. Several hydrophobic amino acids in the p53 N-terminal domain are required for transcriptional activation, binding to mdm-2 and the Adenovrius 5 EIB 55kd protein.  Genes and Development. Vol. 8. : 1235-1246.
• Lin, J, Simmons, DT. 1991. Stable T-p53 complexes are not required for replication of simian virus 40 in culture or for enhanced phosphorylation of T antigen and p53.  J or Virology. Vol. 65. : 2066-2072.
• Lin, J, Simmons, DT. 1991. The ability of large T antigen to complex with p53 is necessary for the increased life span and partial transformatoin of human cells by SV40.  J of Virology. Vol. 65. : 6447-6453.
• Lin, J, Simmons, DT. 1990. Transformation by simian virus 40 does not involve the mutational activation of p53 to an oncogenic form.  Virology. Vol. 176. : 302-305.
• Lee, Y, Lin, J, Pao, CC, Lo, SJ. 1988. Enhanced production of hepatitis B virus surface antigen in mouse C127 cell on a bovine papillomavirus-metallothionein vector.  Biochemistry International. Vol. 16. : 101-109.